Literature DB >> 12372733

New syndrome characterized by hypomyelination with atrophy of the basal ganglia and cerebellum.

Marjo S van der Knaap1, SakkuBai Naidu, Petra J W Pouwels, Simona Bonavita, Rudy van Coster, Lieven Lagae, Jürgen Sperner, Robert Surtees, Raphael Schiffmann, Jakob Valk.   

Abstract

BACKGROUND AND
PURPOSE: Leukoencephalopathies of unknown origin constitute a considerable problem in child neurology. The purpose of our ongoing study of the subject was to define new disease entities among them by using primarily MR imaging pattern recognition.
METHODS: We identified seven unrelated patients with a distinct MR imaging pattern consisting of hypomyelination and atrophy of the basal ganglia (neostriatum) and cerebellum (H-ABC). We reviewed the clinical, MR imaging, MR spectroscopic, and laboratory data.
RESULTS: Clinically, the patients' diseases were characterized by variably disturbed early development followed by increasing extrapyramidal movement abnormalities, ataxia, and spasticity. Mental capacity was variably affected, but it appeared to be relatively preserved. Parents were not related, and none of their siblings were affected. No metabolic defect was found. Follow-up MR imaging demonstrated atrophy of the cerebral white matter, neostriatum, and cerebellum, which was most pronounced in the most clinically severe cases. Single-voxel proton MR spectroscopic results were normal in the parietal cortex. In the cerebral white matter, myo-inositol and creatine levels were elevated; this finding was compatible with gliosis. N-acetylaspartate and choline levels were normal, suggesting that neither axonal loss nor active demyelination occurred. Proton MR spectroscopic imaging revealed relatively decreased N-acetylaspartate levels in the frontal region.
CONCLUSION: The uniform and highly characteristic MR imaging findings, in combination with the similarities in the clinical findings, provide evidence of a distinct nosologic entity. The acronym H-ABC is offered to indicate patients sharing these clinical and MR imaging features.

Entities:  

Mesh:

Year:  2002        PMID: 12372733      PMCID: PMC7976795     

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  33 in total

1.  1H and 31P magnetic resonance spectroscopy of the brain in degenerative cerebral disorders.

Authors:  M S van der Knaap; J van der Grond; P R Luyten; J A den Hollander; J J Nauta; J Valk
Journal:  Ann Neurol       Date:  1992-02       Impact factor: 10.422

Review 2.  Concepts of myelin and myelination in neuroradiology.

Authors:  A J Barkovich
Journal:  AJNR Am J Neuroradiol       Date:  2000 Jun-Jul       Impact factor: 3.825

3.  Regional age dependence of human brain metabolites from infancy to adulthood as detected by quantitative localized proton MRS.

Authors:  P J Pouwels; K Brockmann; B Kruse; B Wilken; M Wick; F Hanefeld; J Frahm
Journal:  Pediatr Res       Date:  1999-10       Impact factor: 3.756

4.  Brain involvement in Salla disease.

Authors:  P Sonninen; T Autti; T Varho; M Hämäläinen; R Raininko
Journal:  AJNR Am J Neuroradiol       Date:  1999-03       Impact factor: 3.825

5.  Mutations of MLC1 (KIAA0027), encoding a putative membrane protein, cause megalencephalic leukoencephalopathy with subcortical cysts.

Authors:  P A Leegwater; B Q Yuan; J van der Steen; J Mulders; A A Könst; P K Boor; V Mejaski-Bosnjak; S M van der Maarel; R R Frants; C B Oudejans; R B Schutgens; J C Pronk; M S van der Knaap
Journal:  Am J Hum Genet       Date:  2001-03-06       Impact factor: 11.025

6.  Brain regional distribution pattern of metabolite signal intensities in young adults by proton magnetic resonance spectroscopic imaging.

Authors:  G Tedeschi; A Bertolino; A Righini; G Campbell; R Raman; J H Duyn; C T Moonen; J R Alger; G Di Chiro
Journal:  Neurology       Date:  1995-07       Impact factor: 9.910

7.  Neurophysiological study in Pelizaeus-Merzbacher disease.

Authors:  A Nezu
Journal:  Brain Dev       Date:  1995 May-Jun       Impact factor: 1.961

8.  Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types.

Authors:  J Urenjak; S R Williams; D G Gadian; M Noble
Journal:  J Neurosci       Date:  1993-03       Impact factor: 6.167

9.  The reflection of histology in MR imaging of Pelizaeus-Merzbacher disease.

Authors:  M S van der Knaap; J Valk
Journal:  AJNR Am J Neuroradiol       Date:  1989 Jan-Feb       Impact factor: 3.825

10.  Cockayne syndrome: magnetic resonance images of the brain in a severe form with early onset.

Authors:  H Nishio; S Kodama; T Matsuo; M Ichihashi; H Ito; Y Fujiwara
Journal:  J Inherit Metab Dis       Date:  1988       Impact factor: 4.982

View more
  31 in total

1.  The many faces of TUBB4A mutations.

Authors:  Katja Lohmann; Christine Klein
Journal:  Neurogenetics       Date:  2014-03-21       Impact factor: 2.660

2.  Hypomyelinating leukoencephalopathy.

Authors:  Riaz A Syed
Journal:  Sultan Qaboos Univ Med J       Date:  2013-02-27

Review 3.  Neurological Disorders Associated with Striatal Lesions: Classification and Diagnostic Approach.

Authors:  Davide Tonduti; Luisa Chiapparini; Isabella Moroni; Anna Ardissone; Giovanna Zorzi; Federica Zibordi; Sergio Raspante; Celeste Panteghini; Barbara Garavaglia; Nardo Nardocci
Journal:  Curr Neurol Neurosci Rep       Date:  2016-06       Impact factor: 5.081

4.  Mutations in POLR3A and POLR3B encoding RNA Polymerase III subunits cause an autosomal-recessive hypomyelinating leukoencephalopathy.

Authors:  Hirotomo Saitsu; Hitoshi Osaka; Masayuki Sasaki; Jun-Ichi Takanashi; Keisuke Hamada; Akio Yamashita; Hidehiro Shibayama; Masaaki Shiina; Yukiko Kondo; Kiyomi Nishiyama; Yoshinori Tsurusaki; Noriko Miyake; Hiroshi Doi; Kazuhiro Ogata; Ken Inoue; Naomichi Matsumoto
Journal:  Am J Hum Genet       Date:  2011-10-27       Impact factor: 11.025

Review 5.  A FOXG1 mutation in a boy with congenital variant of Rett syndrome.

Authors:  Tangui Le Guen; Nadia Bahi-Buisson; Juliette Nectoux; Nathalie Boddaert; Yann Fichou; Bertrand Diebold; Isabelle Desguerre; Florence Raqbi; Valérie Cormier Daire; Jamel Chelly; Thierry Bienvenu
Journal:  Neurogenetics       Date:  2010-08-24       Impact factor: 2.660

6.  Invited article: an MRI-based approach to the diagnosis of white matter disorders.

Authors:  Raphael Schiffmann; Marjo S van der Knaap
Journal:  Neurology       Date:  2009-02-24       Impact factor: 9.910

Review 7.  Tools for diagnosis of leukodystrophies and other disorders presenting with white matter disease.

Authors:  Adeline Vanderver
Journal:  Curr Neurol Neurosci Rep       Date:  2005-03       Impact factor: 5.081

8.  Expansion of the spectrum of TUBB4A-related disorders: a new phenotype associated with a novel mutation in the TUBB4A gene.

Authors:  Lubov Blumkin; Ayelet Halevy; Dominique Ben-Ami-Raichman; Dvir Dahari; Ami Haviv; Cohen Sarit; Dorit Lev; Marjo S van der Knaap; Tally Lerman-Sagie; Esther Leshinsky-Silver
Journal:  Neurogenetics       Date:  2014-02-14       Impact factor: 2.660

9.  A de novo mutation in the β-tubulin gene TUBB4A results in the leukoencephalopathy hypomyelination with atrophy of the basal ganglia and cerebellum.

Authors:  Cas Simons; Nicole I Wolf; Nathan McNeil; Ljubica Caldovic; Joseph M Devaney; Asako Takanohashi; Joanna Crawford; Kelin Ru; Sean M Grimmond; David Miller; Davide Tonduti; Johanna L Schmidt; Robert S Chudnow; Rudy van Coster; Lieven Lagae; Jill Kisler; Jürgen Sperner; Marjo S van der Knaap; Raphael Schiffmann; Ryan J Taft; Adeline Vanderver
Journal:  Am J Hum Genet       Date:  2013-04-11       Impact factor: 11.025

10.  TUBB4A de novo mutations cause isolated hypomyelination.

Authors:  Amy Pizzino; Tyler Mark Pierson; Yiran Guo; Guy Helman; Sebastian Fortini; Kether Guerrero; Sulagna Saitta; Jennifer Louise Patrick Murphy; Quasar Padiath; Yi Xie; Hakon Hakonarson; Xun Xu; Tara Funari; Michelle Fox; Ryan J Taft; Marjo S van der Knaap; Geneviève Bernard; Raphael Schiffmann; Cas Simons; Adeline Vanderver
Journal:  Neurology       Date:  2014-08-01       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.